RS
SMMT icon

Rakuten Securities’s Summit Therapeutics SMMT Stock Holding History

Rakuten Securities’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.78K Buy
465
+460
+9,200% +$8.16K ﹤0.01% 516
2026
Q1 		$95 Hold
5
– – ﹤0.01% 834
2025
Q4 		$87 Hold
5
– – ﹤0.01% 854
2025
Q3 		$103 Buy
+5
New +$121 ﹤0.01% 863
2025
Q1 		– Sell
-4,000
Closed -$71.4K – 857
2024
Q4 		$71.4K Buy
+4,000
New +$77.5K 0.03% 179

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Rakuten Securities's SMMT Position: Q2 2026 in Review

Rakuten Securities increased its Summit Therapeutics (SMMT) stake by 9,200% in Q2 2026, buying an estimated $8.16K and bringing the position to 465 shares worth $6.78K. The position accounts for ﹤0.01% of the portfolio, ranked #516.

Rakuten Securities first reported a position in SMMT in Q4 2024 and has held it in 5 quarters since. The position peaked at $71.4K in Q4 2024. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Rakuten Securities held 465 shares of Summit Therapeutics worth $6.78K as of Q2 2026.
  • Rakuten Securities bought 460 Summit Therapeutics shares in Q2 2026, an estimated $8.16K.
  • Summit Therapeutics made up ﹤0.01% of Rakuten Securities's portfolio in Q2 2026, its #516 holding.
  • Rakuten Securities first reported a position in Summit Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Rakuten Securities's Summit Therapeutics position peaked at $71.4K in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Rakuten Securities's 13F filing for Q2 2026, filed 12 Aug 2026.